Shield Therapeutics (LON:STX) reports it has achieved the best possible outcome for Feraccru. The US Food & Drug Administration (FDA) has approved the treatment for a broad label to treat iron deficiency (ID) in adults, addressing a population many times wider than the iron deficiency anaemia (
29 Jul 2019
Shield Therapeutics PLC: FDA approves broad label for Feraccru
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Shield Therapeutics PLC: FDA approves broad label for Feraccru
Shield Therapeutics Plc (STX:LON) | 2.0 0 0.0% | Mkt Cap: 15.6m
- Published:
29 Jul 2019 -
Author:
Emma Ulker -
Pages:
4
Shield Therapeutics (LON:STX) reports it has achieved the best possible outcome for Feraccru. The US Food & Drug Administration (FDA) has approved the treatment for a broad label to treat iron deficiency (ID) in adults, addressing a population many times wider than the iron deficiency anaemia (